SCORCH
- 06 Nov 2006 09:34
This company has been steadily moving up in the last month after sealing a 95m deal with a major pharmaceutical , good press on the weekend is now making it move ahead.
Brokers target is short term 40p.
DYOR
SCORCH
- 23 Nov 2006 18:20
- 18 of 26
Shares mag have today stated that the SPA share price still has got a long way to go with a price target of 73p , currently 43p.
SCORCH
- 06 Dec 2006 18:27
- 19 of 26
Offer now 53.5p it's more than tripled since the beginning of November and will continue to rise on good news about latest trials.
SCORCH
- 11 Jan 2007 18:17
- 20 of 26
Well on its way to 73p price target , currently 64.5p . More than tripled in last 2 months and will not be surprised to see it go over 100p after next set of news reports on its cancer technology.
tiku
- 09 Feb 2007 08:15
- 21 of 26
anybody know why SPA moving so sharply today?
Barefoot
- 24 Mar 2007 00:22
- 22 of 26
quiet on here but a good company to watch.........news coming shortly from what ive heard...;o)
hlyeo98
- 30 Mar 2007 10:05
- 23 of 26
Bad news though...
SR Pharma annual losses widen
AFX
LONDON (AFX) - SR Pharma PLC, which specialises in RNAi-based therapeutics, reported widening annual losses on higher research and development costs, and forecast a significant hike in spending this year.
The company also said it plans to change its name to Silence Therapeutics.
Pretax losses in 2006 came in at 3.9 mln stg, compared to 3.6 mln the previous year.
Revenues surged four-fold to 1.95 mln stg, while R&D spend almost doubled to 3.2 mln stg.
During 2007 the group is forecasting a significant increase in R&D and infrastructure costs, as its lead molecules move into the clinic for human testing, and as US operations are set up.
SR Pharma said those costs will be funded through a continuation of collaboration and licensing deals with major pharmaceutical and biotechnology companies, on which it is in talks with a number of potential parties.
The company has called an Extraordinary General Meeting to approve the name change, and permission to issue new shares.
The group ended the year with 8.8 mln stg in cash.
SR Pharma shares, which have surged 440 pct in the last six months, closed Thursday at 81 pence, valuing the company at 92 mln stg.
SCORCH
- 27 Apr 2007 08:25
- 24 of 26
Price now 92.75p and rising , this is going to be the best performing share on aim.
Barefoot
- 30 Apr 2007 00:55
- 25 of 26
have to agree Scorch....been in since 22p...;o)
Barefoot
- 30 Apr 2007 00:56
- 26 of 26
hlyeo98....yoo should take a look at the advfn thread....lots of good info there....most of it true from what i can gather...;o)